hMG 150iu Injection (Menotrophin)

Product Overview

hMG 150iu Injection, marketed under the brand name Menotrophin, is a pharmaceutical preparation supplied by Sanzyme Biologics (P) Ltd. The product is indicated for the treatment of female infertility, male hypogonadism, and male infertility. Each package contains a single 150‑International Unit (IU) injection delivered in a sterile vial. Available pack sizes include 10, 20, and 5 vials, allowing clinicians to select the most appropriate quantity for their practice. The active ingredient is a purified form of human menopausal gonadotropin (HMG), a hormone that stimulates the gonads in both sexes. This medication is classified under the category of Female Infertility and is intended for parenteral administration only.

What is hMG 150iu Injection (Menotrophin)

hMG 150iu Injection, commonly referred to as Menotrophin, belongs to a class of gonadotropin‑releasing agents derived from the urine of post‑menopausal women. The drug contains a mixture of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity, collectively referred to as human menopausal gonadotropin. In clinical practice, Menotrophin is used to augment ovarian stimulation in assisted reproductive technologies, to correct hormonal deficiencies in men with hypogonadism, and to improve sperm production in men with certain types of infertility. The 150‑IU strength is the standard dose employed in many treatment protocols, providing a balanced hormonal stimulus that can be titrated according to patient response.

Uses and Benefits

The therapeutic benefits of hMG 150iu Injection are well documented in peer‑reviewed literature. In women, the injection supports follicular development, increasing the likelihood of successful ovulation and pregnancy when combined with assisted reproductive techniques such as in‑vitro fertilisation (IVF). Clinical studies have shown that the use of gonadotropins can raise clinical pregnancy rates by up to 15 % compared with placebo in specific subpopulations. In men, the medication helps to restore endogenous testosterone production, which can improve libido, erectile function, and spermatogenesis. Men with hypogonadotropic hypogonadism often experience a rise in serum testosterone levels after several weeks of treatment, leading to enhanced energy levels and overall quality of life. The medication’s standardized potency (150 IU per vial) ensures consistent dosing, which is essential for achieving predictable hormonal responses.

How It Works

hMG 150iu Injection exerts its effect by binding to receptors on the ovarian granulosa cells and Leydig cells in the testes. The follicle‑stimulating component promotes the growth of ovarian follicles, while the luteinizing component triggers the final maturation step that leads to ovulation. In males, the LH activity stimulates Leydig cells to produce testosterone, whereas the FSH activity acts on Sertoli cells to support spermatogenic cells. The hormonal milieu created by the injection mimics the natural surge that occurs during the menstrual cycle, thereby synchronising the endocrine environment needed for reproduction. This mechanism is why Menotrophin is considered a cornerstone agent in controlled ovarian hyperstimulation protocols.

Dosage Guidelines

Dosage of hMG 150iu Injection must be individualized based on the patient’s age, ovarian reserve, response to prior therapy, and underlying diagnosis. For female patients undergoing controlled ovarian stimulation, a typical initiating dose is 150 IU administered subcutaneously or intramuscularly, with subsequent adjustments guided by ultrasound monitoring of follicular size. In male patients with hypogonadism, the recommended regimen often starts with 150 IU weekly, with dose escalation up to 300 IU per week if testosterone levels remain suboptimal after four weeks. It is essential to follow the prescribing clinician’s instructions and to avoid exceeding the maximum recommended weekly dose, which should not surpass 750 IU without medical supervision. Patients should be instructed to store the vial at 2‑8 °C until use and to discard any medication that has been left at room temperature for more than 24 hours.

Side Effects

Like all hormonal medications, hMG 150iu Injection can be associated with adverse effects. The most commonly reported side effects include mild abdominal discomfort, bloating, and injection‑site reactions such as redness or swelling. Less frequent but clinically significant events may involve ovarian hyperstimulation syndrome (OHSS), which can manifest as severe pelvic pain, nausea, and shortness of breath. In men, supraphysiological testosterone levels may lead to acne, fluid retention, or increased hematocrit. Patients should be advised to report any sudden weight gain, visual disturbances, or signs of allergic reaction (such as rash, itching, or difficulty breathing) to their healthcare provider immediately. Early recognition of OHSS and prompt medical intervention are crucial to preventing serious complications.

Warnings and Precautions

Before initiating treatment with Menotrophin, clinicians should assess patients for contraindications such as ovarian cysts, endometrial hyperplasia, or uncontrolled thyroid disease. Women who are pregnant or breastfeeding must not receive this medication. Prior to therapy, a baseline hormonal panel and pelvic ultrasound are recommended to evaluate ovarian morphology and to rule out underlying pathologies. Men with a history of prostate cancer or severe cardiovascular disease should be evaluated carefully, as hormonal manipulation may exacerbate these conditions. Concurrent use of other gonadotropins or exogenous sex steroids should be avoided unless specifically indicated. Patients should be instructed to inform their physician of any medications that may interact with hormonal therapies, including anticoagulants, antiepileptics, or corticosteroids.

Frequently Asked Questions

Q: What is the difference between hMG 150iu Injection and recombinant FSH products?
A: hMG is extracted from the urine of post‑menopausal women and contains a mixture of FSH and LH activities, whereas recombinant FSH is a single‑hormone preparation produced by biotechnology. This mixture can provide a broader hormonal stimulus that some clinicians find advantageous for certain patient profiles.

Q: How many cycles of treatment are typically recommended?
A: The number of treatment cycles depends on the individual’s response and the underlying diagnosis. Many protocols limit the total number of stimulation cycles to three to four attempts before considering alternative interventions, to minimise cumulative exposure and cost.

Q: Can hMG 150iu Injection be used for weight loss or bodybuilding?
A: No. The medication is indicated solely for reproductive health conditions. Off‑label use for performance enhancement is not supported by clinical evidence and may pose significant health risks.

Q: Is the medication safe for patients with a history of blood clots?
A: Patients with a personal or family history of thromboembolic disorders should discuss the risks with their physician, as hormonal therapies can influence clotting factors.

Q: Where can I find more detailed prescribing information?
A: The full product label and prescribing information are available through the manufacturer’s website and can also be accessed via the FDA’s drug database at FDA Drug Labels.

Related Products

• Letrozole 2.5 mg (Generic)
• Estradiol 2 mg (Generic)
• Progesterone 50 mg Injection (Generic)
• Menotropin HMG 150iu Injection (Generic)
• Menotropin HMG 75iu Injection (Generic)
• IVFhMG 75iu (Menotrophin [HMG])
• IVFhMG 150iu (Menotrophin [HMG])
• hMG 1200iu Injection (Menotrophin)
• hCG 10000iu Injection (Human Chorionic Gonadotropin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)
• hMG 75iu Injection (Menotrophin)
• ZyHMG 75iu Injection (Menotrophin [HMG])